Novo Nordisk is about to have a very bad weekend. The Danish pharma giant’s patent on semaglutide — the active ingredient in both Ozempic and Wegovy — expires Saturday in India, China, and several other heavily populated countries. Generic versions are expected to hit Indian pharmacies almost immediately, with Canada, Brazil, Turkey, and South Africa following in the coming months.
We’re talking about generic versions of one of the most commercially successful drugs in history becoming available to billions of people at prices as low as $3 per month. For context, Americans without insurance currently pay hundreds of dollars out of pocket for the same medication.
This is a massive blow to Novo Nordisk, which has already been losing ground to Eli Lilly’s competing GLP-1 drugs Mounjaro (for diabetes) and Zepbound (for obesity). Lilly has a critical advantage here — its patents are expected to hold for at least another decade in most major markets. That makes Lilly the clear competitive winner in the GLP-1 wars as Novo’s moat evaporates in key international markets.
The ripple effects are already visible. Chinese manufacturers have been producing semaglutide versions that are being sold in global markets, including compounded versions marketed to American consumers. Once generics arrive in Canada — where Novo’s patent protection expired in January — experts predict a wave of U.S. customers will order from Canadian pharmacies, further eroding Novo’s pricing power in its most profitable market.
For investors, the calculus here is straightforward. Novo Nordisk just struck a deal with the Trump administration to cut prices in exchange for tariff relief, but those cuts don’t go nearly as deep as generic competition will. The company’s global revenue trajectory just got significantly harder to defend. Meanwhile, Eli Lilly sits in the catbird seat — patent-protected, gaining market share, and watching its biggest rival get undercut by $3 generics.
The broader GLP-1 market isn’t shrinking — it’s exploding. These drugs have been shown to help prevent heart attacks and strokes, not just manage weight and diabetes. The addressable market is enormous. But the question for investors is no longer whether GLP-1 drugs will be huge. It’s which companies will capture the profits, and which will watch them evaporate. As of this Saturday, the answer to that question gets a lot clearer.
